MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jmg-2026-111529

Медицинская библиотека · Journal of medical genetics · 2026

Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial.

Saxena Anurag, Drew Cheney Jg, Cannings-John Rebecca, Pickles Timothy, Mills Laura J, McDermott Emer, Angel Lianna, McNamara Rachel, Smalley Michelle, Randell Elizabeth, Joss Shelagh K, Donnelly Deirdre E, Davies David Mark, Owen-Jones Eleri, Kirby Nigel, de Vries Petrus J, Hood Kerry, Sampson Julian R

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Mammalian target of rapamycin (mTOR) inhibitors are effective treatments for tumours and epilepsy in tuberous sclerosis complex (TSC). This study aimed to determine the effects of the mTOR inhibitor everolimus and a placebo on neuropsychological functioning in TSC.

METHODS

Individuals with TSC aged 16-60 years and intelligence quotient >60 who scored ≤5th percentile in one or more of 10 memory or executive function variables from the Brain Injury Rehabilitation Trust Memory and Information Processing Battery, the Cambridge Neuropsychological Test Automated Battery and the Test of Everyday Attention were randomised 2:1 to 24 weeks everolimus or placebo and retested at baseline and 4, 12, 24 and 36 weeks. The primary outcome was the proportion of responders, defined as improvement by ≥1 SD in at least one variable.

RESULTS

38 participants were randomised, of whom 23 in the everolimus arm and 12 in the placebo arm completed all primary endpoint assessments and were included in outcome analyses. Effect sizes for individual neuropsychological variables were small to medium (Cohen's d=0-0.465), but 20 of 23 (87%, 95% CI 67.9 to 95.5) in the everolimus arm and 9 of 12 (75%, 95% CI 46.8 to 91.1) in the placebo arm were responders. Adverse events were reported in 22/25 (88%) of those randomised to everolimus versus 8/13 (61.5%) for placebo.

DISCUSSION: The large proportions of responders in both trial arms may reflect unexpectedly large familiarity, practice or placebo effects in TSC, psychometric issues with parallel test forms and how a response was defined. Our findings may inform the design of future trials of neuropsychological functioning in TSC and similar conditions.

TRIAL REGISTRATION NUMBER: ISRCTN09739757 and NCT01954693.

Для цитирования: Saxena Anurag, Drew Cheney Jg, Cannings-John Rebecca, Pickles Timothy, Mills Laura J, McDermott Emer, Angel Lianna, McNamara Rachel, Smalley Michelle, Randell Elizabeth, Joss Shelagh K, Donnelly Deirdre E, Davies David Mark, Owen-Jones Eleri, Kirby Nigel, de Vries Petrus J, Hood Kerry, Sampson Julian R. Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial.. Journal of medical genetics. 2026. DOI: 10.1136/jmg-2026-111529.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.